Mirati reports partial responses in Phase II NSCLC trial of sitravatinib

Mirati Therapeutics Inc. (NASDAQ:MRTX) reported preliminary data from a Phase II trial showing that sitravatinib (MGCD516) in combination with PD-1 mAb Opdivo nivolumab led to 3 confirmed partial responses in 11 evaluable patients with non-squamous non-small cell lung cancer (NSCLC) who progressed on or after treatment with checkpoint inhibitor therapy. The company said the predefined criteria for expansion from stage 1 to stage 2 of the open-label, U.S. trial, which will enroll a combined total of 34 patients, have been met. Data were presented at the International Association for the Study of Lung Cancer (IASLC) Multidisciplinary Symposium in Thoracic Oncology in Chicago.

Mirati also presented a case study from a heavily pretreated NSCLC patient harboring an inactivating Cbl proto-oncogene (CBL) mutation in a Phase Ib trial evaluating sitravatinib as monotherapy. The company said the patient achieved a confirmed partial response with a maximum reduction in target lesions of 77%...